{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-089245","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2025-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.302890+00:00","generated_at":"2026-05-17T06:52:46.286877+00:00","sec_items":["7.01","9.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AbbVie settles RINVOQ patent litigation; no generic entry until at least April 2037","bullets":["Settled litigation with all generic manufacturers over RINVOQ (upadacitinib) ANDAs.","No generic entry expected before April 2037 in the US, assuming pediatric exclusivity.","Extends AbbVie's market exclusivity for RINVOQ, a key immunology drug.","Settlement and license agreements subject to standard acceleration provisions.","Removes a significant overhang for AbbVie's revenue stream."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-089245","json":"https://secwatch.observer/filing/0001104659-25-089245.json","markdown":"https://secwatch.observer/filing/0001104659-25-089245.md","text":"https://secwatch.observer/filing/0001104659-25-089245.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000110465925089245/0001104659-25-089245-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000110465925089245/tm2525781d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:52:46.286877+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}